menu
    • menu
    [{"orgOrder":0,"company":"Avextra","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Avextra","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avextra \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avextra \/ Undisclosed"},{"orgOrder":0,"company":"Avextra","sponsor":"German Pain Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Collaboration","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Avextra","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avextra \/ German Pain Association","highestDevelopmentStatusID":"1","companyTruncated":"Avextra \/ German Pain Association"},{"orgOrder":0,"company":"Avextra","sponsor":"Italian Ministry of Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Avextra","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avextra \/ Italian Ministry of Health","highestDevelopmentStatusID":"8","companyTruncated":"Avextra \/ Italian Ministry of Health"}]

    Find Clinical Drug Pipeline Developments & Deals by Avextra

    Menu

    Avextra

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Avextra

                            Germany arrow
                            AAPS
                            Not Confirmed

                            Avextra

                            Germany arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Italian Ministry of Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Avextra Backs Phase II Trial in Italy on Cannabis for Neurodegenerative Diseases

                            Details : A new controlled substance is being developed for the treatment of amyotrophic lateral sclerosis (ALS).

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            October 24, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Italian Ministry of Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Avextra

                            Germany arrow
                            AAPS
                            Not Confirmed

                            Avextra

                            Germany arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Avextra's Cannabis Medicine NEUROBIS Gets Phase II Trial Approval in Italy

                            Details : Cannabisextrakt Avextra is an oral cannabinoid formulation which is currently being evaluated for the treatment of neurodegenerative diseases such as ALS, Alzheimer’s Disease and Parkinson’s Disease.

                            Product Name : Cannabisextrakt Avextra

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            October 08, 2024

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Avextra

                            Germany arrow
                            AAPS
                            Not Confirmed

                            Avextra

                            Germany arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol,Cannabidiol

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : German Pain Association

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            German Pain Association and Avextra Join Forces To Launch New Study Ocean

                            Details : The company aims to focus on the clinical advancement of THC , a partial agonist of the CB1 receptor with Cannabidiol, evaluated for chemotherapy-induced neuropathic pain treatment.

                            Product Name : THC:CBD

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            January 23, 2024

                            Lead Product(s) : Tetrahydrocannabinol,Cannabidiol

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : German Pain Association

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth